We bring our concepts to develop new treatments for patients with Parkinson disease (PD) to pioneering researchers with the intent to advance neuroscience breakthroughs into differentiated medicines for patients with PD.
innovation
vision
Combining excellent clinical understanding and patient centric programs with cutting-edge technologies for the development of new treatment for Parkinson disease requires exceptional performance at every level. A sustainable and responsible development and long-term growth strategy for our company will include criteria and metrics that demonstrate our commitment as a medical doctors, scientists and entrepreneurs, including our commitment to patients, employees, customers, and investors, along with the communities where we work and live.
science
We share our concepts for developing new treatments for patients with Parkinson's disease (PD) with innovative research, aiming to advance neuroscience breakthroughs into specialized medicines. The identification of the link between mutations in the Gaucher gene, known as GBA1, responsible for encoding the lysosomal enzyme glucocerebrosidase, and synucleinopathies, directly emerged from the clinical recognition of Gaucher disease patients exhibiting Parkinsonism. Mutations in the glucocerebrosidase gene (GBA1) represent the most prevalent known genetic risk factor for PD.
Understanding the connection between glucocerebrosidase and alpha-synuclein has led to novel therapeutic approaches for Gaucher disease andGBA1-related PD. This insight highlights the role of the Endoplasmic Reticulum (ER) and the chronic stress it undergoes due to the misfolding of the glucocerebrosidase enzyme caused by mutations. Unlike current Gaucher disease treatments, new small molecule therapies, including competitive and non-competitive chaperones like ambroxol, aim to boost glucocerebrosidase. These drugs, demonstrated to enhance glucocerebrosidase activity in various disease models, hold potential for treating Gaucher disease and GBA1-related PD, and may even prevent the early stages of PD development before symptoms arise.
academic collaborators
Shaare Zedek Medical Center, Jerusalem, Israel
Rostock University, Rostock, Germany
Tel-Aviv University, Tel-Aviv, Israel
Columbia University, New York, USA
partnering
Deep and honest relationships are at the core of our innovation ecosystem; it is a system of co-creation. The Parkinson-treatment innovation program is based on mutual respect for the expertise that each partner brings. Our research partners bring unique knowledge of the biology of Parkinson disease. Agyany can contribute its clinical and basic science skills in genetic neurodegenerative diseases and provide a pathway to transform a breakthrough into a clinical development candidate.
investors
Agyany is an innovation driven company that intends to develop cutting – edge concepts for the treatment of Parkinson disease, mostly genetically based etiologies. We are developing a corporate governance structure that is designed to empower the senior executives to drive all business goals and create long term value for our investors, while ensuring proper checks and balances to guarantee transparency, integrity, and accountability for the way we implement our strategies.
